Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo have withdrawn their Biologics License Application for ifinatamab deruxtecan after the FDA determined Phase 2 data from the IDeate-Lung01 trial failed to meet accelerated approval requirements. The drug targeted extensive-stage small cell lung cancer. This regulatory setback impacts a licensing agreement worth up to $22 billion, which included a $4 billion upfront payment. Despite the withdrawal, both companies are maintaining patient enrollment for the Phase 3 IDeate-Lung02 trial to seek further evidence of efficacy.
Listen to Live Briefing
Real-time synthesized voice briefing ยท Live Feeds Desk
- โ Merck and Daiichi Sankyo withdrew their Biologics License Application for ifinatamab deruxtecan.
- โ The FDA ruled that Phase 2 data from the IDeate-Lung01 trial did not meet accelerated approval requirements.
- โ The licensing deal is valued at up to $22 billion and includes a $4 billion upfront payment.
- โ Patient enrollment continues for the Phase 3 IDeate-Lung02 trial.
What changed
No new factual developments regarding the ifinatamab deruxtecan filing were provided in the latest source materials.
Live updates
-
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Application
Merck and Daiichi Sankyo have withdrawn their Biologics License Application for ifinatamab deruxtecan after the FDA determined Phase 2 data from the IDeate-Lung01 trial failed to meet accelerated approval requirements. The drug targeted extensive-stage small cell lung cancer. This regulatory setback impacts a licensing agreement worth up to $22 billion, which included a $4 billion upfront payment. Despite the withdrawal, both companies are maintaining patient enrollment for the Phase 3 IDeate-Lung02 trial to seek further evidence of efficacy.
Why it matters
The deal represents a significant financial commitment between the two pharmaceutical giants. The failure to secure accelerated approval delays the market entry of a potential treatment for a high-need cancer type. Future viability now rests on the outcome of the ongoing Phase 3 study.
What is confirmed
- Merck and Daiichi Sankyo withdrew their Biologics License Application for ifinatamab deruxtecan.
- The FDA ruled that Phase 2 data from the IDeate-Lung01 trial did not meet accelerated approval requirements.
- The licensing deal is valued at up to $22 billion and includes a $4 billion upfront payment.
- Patient enrollment continues for the Phase 3 IDeate-Lung02 trial.
What to watch next
- Results from the Phase 3 IDeate-Lung02 trial
- Any subsequent FDA guidance on the requirements for a new application
confidence 100%Sources used for this update (3)
- www.pdufa.bio โ FDA Decisions Archive: 485 Tracked, Updated Daily | pdufa.bio
- www.biospace.com โ Lung cancer - BioSpace
- www.marketscreener.com โ Silence Therapeutics Enters into Agreement to be Acquired by ...
-
Merck and Daiichi Sankyo withdraw lung cancer drug application
Merck and Daiichi Sankyo have pulled their Biologics License Application for ifinatamab deruxtecan. The drug was intended for extensive-stage small cell lung cancer, but the FDA ruled that Phase 2 data from the IDeate-Lung01 trial did not meet the requirements for accelerated approval. This setback affects a licensing deal valued at up to $22 billion, which includes a $4 billion upfront payment. While the application is withdrawn, the companies are continuing patient enrollment for the Phase 3 IDeate-Lung02 trial.
Why it matters
The partnership aims to develop three cancer candidates to replace revenue lost as Keytruda faces future declines. This specific drug candidate is a key part of that strategic transition.
Still unconfirmed
- Merck and Daiichi Sankyo withdrew their Biologics License Application for ifinatamab deruxtecan after the FDA found Phase 2 IDeate-Lung01 data insufficient for accelerated approval.
- The drug is part of a licensing agreement worth up to $22 billion with $4 billion upfront.
- Patient enrollment is ongoing for the Phase 3 IDeate-Lung02 trial.
What to watch next
- Results from the IDeate-Lung02 Phase 3 trial.
- FDA guidance on requirements for a future filing of ifinatamab deruxtecan.
confidence 70%Sources used for this update (3)
- www.merck.com โ Contact us - Merck.com
- www.biopharmadive.com โ Pharma News | BioPharma Dive
- stockanalysis.com โ Daiichi Sankyo Company (TYO:4568) Stock Price & Overview
-
Merck and Daiichi Pull Lung Cancer BLA After FDA Pushback
Merck and Daiichi Sankyo withdrew their Biologics License Application for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer after discussions with the FDA. The regulatory agency determined that Phase 2 data from the IDeate-Lung01 trial failed to satisfy accelerated approval standards. The drug candidate is part of a massive licensing agreement worth up to $22 billion, which includes $4 billion upfront and covers three cancer candidates intended to help offset future revenue losses from Keytruda. Patient enrollment continues in the separate Phase 3 IDeate-Lung02 trial.
Why it matters
The withdrawal represents a setback for the antibody-drug conjugate pact between Merck and Daiichi Sankyo. Merck, known as MSD outside the US and Canada, relies on these pipeline assets to mitigate impending patent expirations for its top-selling cancer immunotherapy Keytruda in 2028. The companies originally secured rights to ifinatamab deruxtecan alongside two other candidates under the multi-billion-dollar agreement.
What is confirmed
- Merck and Daiichi Sankyo voluntarily withdrew their Biologics License Application for ifinatamab deruxtecan for relapsed extensive-stage small cell lung cancer.
- The decision followed FDA discussions determining that Phase 2 trial data from IDeate-Lung01 did not meet accelerated approval requirements.
- The companies are continuing patient enrollment in the Phase 3 IDeate-Lung02 trial comparing the drug to physician-selected chemotherapy.
- The partnership involved a $4 billion upfront payment for three cancer candidates in a deal potentially worth up to $22 billion.
What to watch next
- Results from the ongoing Phase 3 IDeate-Lung02 trial evaluating ifinatamab deruxtecan against chemotherapy
- Future regulatory guidance on the clinical development path for the B7-H3-directed antibody-drug conjugate
confidence 100%Sources used for this update (9)
- www.rttnews.com โ Biotech & Pharma News, Stocks, FDA Decision, Clinical Trials - RTTNews
- www.merckconnect.com โ Log in to MerckConnect.com
- www.oncologynurseadvisor.com โ Ifinatamab Deruxtecan BLA Withdrawn for Relapsed ES-SCLC
- www.biospace.com โ Regulatory - BioSpace
- www.rttnews.com โ Merck & Co Inc. (MRK) News Headlines - RTTNews
- pharmaphorum.com โ MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo
- www.marketbeat.com โ DSNKY News Today | Why did Daiichi Sankyo stock go down today?
- www.biospace.com โ Merck & Co. - BioSpace
- www.marketscreener.com โ Daiichi Sankyo Company, Limited: Official Announcements ...
-
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Application After FDA Pushback
Merck and Daiichi Sankyo have voluntarily withdrawn their Biologics License Application for ifinatamab deruxtecan (I-DXd) intended to treat adult patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). The decision follows discussions with the FDA, which determined that data from the IDeate-Lung01 Phase 2 trial did not meet the requirements for accelerated approval. While this application is scrapped, the companies are continuing patient enrollment in the Phase 3 IDeate-Lung02 trial to evaluate the drug against physician-selected chemotherapy.
Why it matters
This setback affects a $4B partnership between the two companies and represents the second partnered cancer therapy application they have pulled in the US. RBC Capital Markets suggests the withdrawal benefits competitors like Roche and GSK. The drug is a B7-H3 antibody-drug conjugate.
What is confirmed
- Merck and Daiichi Sankyo voluntarily withdrew the Biologics License Application for ifinatamab deruxtecan in adult patients with extensive-stage small cell lung cancer.
- The FDA stated the companies lacked sufficient data for accelerated approval, including data from the IDeate-Lung01 Phase 2 trial.
- Patient enrollment is continuing in the IDeate-Lung02 Phase 3 trial comparing the drug to chemotherapy.
- The withdrawal impacts a $4B deal between the two firms.
Still unconfirmed
- RBC Capital Markets views the withdrawal as a net positive for rivals GSK and Roche.
- The withdrawal is a setback for the HER3 programme ahead of a data readout at ASCO.
What to watch next
- Results from the IDeate-Lung02 Phase 3 trial
- Data readout at ASCO regarding the HER3 programme
confidence 100%Sources used for this update (21)
- Fierce Biotech โ Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
- Reuters โ Merck, Daiichi pull US application for second partnered cancer therapy
- OncLive โ Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
- Endpoints News โ Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
- FirstWord โ Vital Signs: Twice bitten, thrice shy for Merck and Daiichi's ADC aspirations
- BioSpace โ Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
- www.merck.com โ Merck | Home
- jobs.merck.com โ Discover Job Opportunities at Merck | Merck Careers
- jobs.merck.com โ Your job search results | Merck Careers
- www.merck.com โ Products list - Merck.com
- www.fiercebiotech.com โ Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal | Fierce Biotech
- www.merck.com โ Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensiv....
Community Sentiment: How do you assess this situation?
Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community